Comparative pharmacoeconomic analysis of the use of Bonviva® (ibandronat) to prevent fractures in postmenopausal osteoporosis

Comparative pharmacoeconomic analysis of the use of Bonviva® (ibandronat) to prevent fractures in postmenopausal osteoporosis

Objective: to make a pharmacoeconomic analysis of the use of oral (a 150-mg tablet once a month) and injectable (a solution for intravenous bolus injection of 3 mg in 3 ml once every 3 months) ibandronate in patients with postmenopausal osteoporosis (OP). Material and methods. The cost minimization...

Full description

Bibliographic Details
Main Authors: E A Pyadushkina, K V Gerasimova, S V Goryainov, Vitaly Vladimirovich Omelyanovsky, M V Avksentyeva, I S Krysanov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2012-12-01
Series:Современная ревматология
Subjects:
osteoporosis
ibandronate
bisphosphonates
strontium ranelate
analysis of cost minimization
analysis of budgetary impact
Online Access:https://mrj.ima-press.net/mrj/article/view/456

Internet

https://mrj.ima-press.net/mrj/article/view/456

Similar Items